Evidence map›Paper›PMID 32678948›Full record

ArticleBritish journal of haematology2020

Clinical outcomes and risk factors for severe COVID-19 in patients with haematological disorders receiving chemo- or immunotherapy.

Thomas A Fox, Ethan Troy-Barnes, Amy A Kirkwood, Wei Yee Chan, James W Day, Selina J Chavda, Emil A Kumar, Kate David, Oliver Tomkins, Emilie Sanchez and 9 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of haematology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 10 pooled it
5.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 10 syntheses or guidelines pooled it, 76 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Trial
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors at 3 institutions in 1 country.

Thomas A FoxDepartment of Haematology, University College London NHS Foundation Trust, London, UK.ORCID 0000-0002-1163-2295
Ethan Troy-BarnesDepartment of Haematology, University College London NHS Foundation Trust, London, UK.
Amy A KirkwoodCR UK & UCL Cancer Trials Centre, UCL Cancer Institute, UCL, London, UK.
Wei Yee ChanDepartment of Haematology, University College London NHS Foundation Trust, London, UK.
James W DayDepartment of Haematology, University College London NHS Foundation Trust, London, UK.ORCID 0000-0002-6329-7636
Selina J ChavdaDepartment of Haematology, University College London NHS Foundation Trust, London, UK.ORCID 0000-0002-1359-9847
Emil A KumarDepartment of Haematology, University College London NHS Foundation Trust, London, UK.
Kate DavidDepartment of Clinical Virology, University College London NHS Foundation Trust, London, UK.
Oliver TomkinsDepartment of Haematology, University College London NHS Foundation Trust, London, UK.ORCID 0000-0002-1059-2906
Emilie SanchezDepartment of Clinical Virology, University College London NHS Foundation Trust, London, UK.
Marie ScullyDepartment of Haematology, University College London NHS Foundation Trust, London, UK.ORCID 0000-0002-2443-6517
Asim KhwajaDepartment of Haematology, University College London NHS Foundation Trust, London, UK.
Jonathan LambertDepartment of Haematology, University College London NHS Foundation Trust, London, UK.
Mervyn SingerUCLH NIHR Biomedical Research Centre, London, UK.
Claire RoddieDepartment of Haematology, University College London NHS Foundation Trust, London, UK.
Emma C MorrisDepartment of Haematology, University College London NHS Foundation Trust, London, UK.
Kwee L YongDepartment of Haematology, University College London NHS Foundation Trust, London, UK.ORCID 0000-0002-6487-276X
Kirsty J ThomsonDepartment of Haematology, University College London NHS Foundation Trust, London, UK.
Kirit M ArdeshnaDepartment of Haematology, University College London NHS Foundation Trust, London, UK.
University College London Hospitals NHS Foundation Trust · GBBury College · GBCRUK Lung Cancer Centre of Excellence · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Haematology patients receiving chemo- or immunotherapy are considered to be at greater risk of COVID-19-related morbidity and mortality. We aimed to identify risk factors for COVID-19 severity and assess outcomes in patients where COVID-19 complicated the treatment of their haematological disorder. A retrospective cohort study was conducted in 55 patients with haematological disorders and COVID-19, including 52 with malignancy, two with bone marrow failure and one immune-mediated thrombotic thrombocytopenic purpura (TTP). COVID-19 diagnosis coincided with a new diagnosis of a haematological malignancy in four patients. Among patients, 82% were on systemic anti-cancer therapy (SACT) at the time of COVID-19 diagnosis. Of hospitalised patients, 37% (19/51) died while all four outpatients recovered. Risk factors for severe disease or mortality were similar to those in other published cohorts. Raised C-reactive protein at diagnosis predicted an aggressive clinical course. The majority of patients recovered from COVID-19, despite receiving recent SACT. This suggests that SACT, where urgent, should be administered despite intercurrent COVID-19 infection, which should be managed according to standard pathways. Delay or modification of therapy should be considered on an individual basis. Long-term follow-up studies in larger patient cohorts are required to assess the efficacy of treatment strategies employed during the pandemic.

Indexed as

ImmunotherapyAdultAgedAged, 80 and overAge FactorsAntineoplastic AgentsBlack PeopleComorbidityCOVID-19Cross InfectionFemaleHematologic DiseasesHematopoietic Stem Cell TransplantationHumansLeukemiaLondonAntineoplastic AgentschemotherapyCovid-19risk factors

Identifiers

PMID32678948
PMCPMC7405103
OpenAlexW3042724950

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.